TNFRSF17 and AL amyloidosis: CAR-T that targets other tumor-associated antigens such as B cell maturation antigen (BCMA) for multiple myeloma (MM)7,8, CD20 for lymphoma and chronic lymphocytic leukemia9 and CD12310 to target acute myeloid leukemia are showing promising results.